Back to search

Peptide record

TPDB05163

Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity standard
31 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB05163
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia ACP740 _ACP240 Antifungipept i2APP AI4AVP dbAMP 3.0 DRAMP DRAVP 2.0 APD_complete APD_hemolytic Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 31-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, ACP740 _ACP240, and other sources, with an available 3D structural model.
Sequence
GSVLNCGETCLLGTCYTTGCTCNKYRVCTKD
Physicochemical Analysis
C134H220N38O47S6
AQHIMFPW
CT
3307.81
7.62
3
2
7
+1
3.03
-0.023
56.45
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
3355
101.43
17
Residue Composition
number
0
A
1
R
2
N
1
D
6
C
1
E
0
Q
4
G
0
H
0
I
3
L
2
K
0
M
0
F
0
P
1
S
6
T
0
W
2
Y
2
V
Amino Acid Distribution
A: 0 R: 1 N: 2 D: 1 C: 6 E: 1 Q: 0 G: 4 H: 0 I: 0 L: 3 K: 2 M: 0 F: 0 P: 0 S: 1 T: 6 W: 0 Y: 2 V: 2
Chemical Descriptors
31
C134H220N38O47S6
3307.81
7.62
+1
3.03
-0.023
Evidence Records 9 records
Evidence 1 Activity

Activity

Antibacterial

Source & Reference

DRAMP

Other

It inhibited HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells (EC50 2500 nM).
Evidence 2 Activity

Activity

Antifungal

Source & Reference

DRAMP Antifungipept

Other

It inhibited HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells (EC50 2500 nM).
Evidence 3 Activity

Activity

Antiparasitic

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
dbAMP 3.0 classified under the Anti-parasitic function class.
It inhibited HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells (EC50 2500 nM).
Evidence 4 Activity

Activity

Antiviral

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Source Activity Label Source Definition
Antiviral
dbAMP 3.0 classified under the Anti-viral function class.
It inhibited HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells (EC50 2500 nM).
Evidence 5 Activity

Activity

% Hemolysis
Hemolysis
7 %
[Ref.20564013] It produced 7% hemolysis at the 62µM.

Source & Reference

Hemolytik APD_complete APD_hemolytic PD_Hemolysis
DRAMP4
Biopolymers. 2008 90(1):51-60.##Biochem J. 2006 Feb 1 393(Pt 3):619-626.##Chembiochem. 2007 Jun 18 8(9):1001-1011.

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation. Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 6 Activity

Activity

Toxicity
Hemolytic
NA | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Kalata B8, a novel antiviral circular protein, exhibits conformational flexibility in the cystine knot motif. | Biochem J | 2006
Evidence 7 Activity

Activity

IC50
Toxicity
>11 µM
Cytotoxic
IC50 | >11 | µM | target cell: CEM-SS cells

Target

CEM-SS cells

Source & Reference

NA
DBAASP
Cyclotides as natural anti-HIV agents | Biopolymers | 2008
Evidence 8 Activity

Activity

IC50
Toxicity
11000 nM
Hemolytic Cytotoxic
Hemolytic_activity: [Ref.20564013] It produced 7% hemolysis at the 62µM. | Cytotoxicity: [Ref.16207177] Kalata B8 inhibited the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells with an antiviral cytoprotective concentration (EC50) of approx. 2.5 µM, while the cytotoxic concentration (IC50) was >11 µM. ##[Ref.18008336]CEM-SS cells:IC50>11000 nM.

Target

erythrocytes

Source & Reference

NA
DRAMP
Biopolymers. 2008 90(1):51-60.##Biochem J. 2006 Feb 1 393(Pt 3):619-626.##Chembiochem. 2007 Jun 18 8(9):1001-1011.
Evidence 9 Hemolysis

Activity

7 %
% Hemolysis
[Ref.20564013] It produced 7% hemolysis at the 62µM.
Hemolysis

Source & Reference

APD_complete APD_hemolytic PD_Hemolysis
Biopolymers. 2008 90(1):51-60.##Biochem J. 2006 Feb 1 393(Pt 3):619-626.##Chembiochem. 2007 Jun 18 8(9):1001-1011.
DRAMP4
APD_complete APD_hemolytic PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation.